| Year |
Citation |
Score |
| 2016 |
Churchill D, Waters L, Ahmed N, Angus B, Boffito M, Bower M, Dunn D, Edwards S, Emerson C, Fidler S, Fisher M, Horne R, Khoo S, Leen C, Mackie N, ... ... Winston A, et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015. Hiv Medicine. 17: s2-s104. PMID 27568911 DOI: 10.1111/hiv.12426 |
0.32 |
|
| 2016 |
Underwood J, Winston A. Guidelines for Evaluation and Management of Cognitive Disorders in HIV-Positive Individuals. Current Hiv/Aids Reports. PMID 27353598 DOI: 10.1007/s11904-016-0324-x |
0.304 |
|
| 2015 |
Winston A, Stöhr W, Antinori A, Arenas-Pinto A, Llibre JM, Amieva H, Cabié A, Williams I, Di Perri G, Tellez MJ, Rockstroh J, Babiker A, Pozniak A, Raffi F, Richert L, et al. Host and disease factors are associated with cognitive function in European HIV-infected adults prior to initiation of antiretroviral therapy. Hiv Medicine. PMID 26611175 DOI: 10.1111/Hiv.12344 |
0.325 |
|
| 2015 |
Ashby J, Foster C, Garvey L, Wan T, Allsop J, Paramesparan Y, Taylor-Robinson SD, Fidler S, Winston A. Cerebral function in perinatally HIV-infected young adults and their HIV-uninfected sibling controls. Hiv Clinical Trials. 16: 81-7. PMID 25874990 DOI: 10.1179/1528433614Z.0000000003 |
0.317 |
|
| 2015 |
Vera JH, Jackson A, Dickinson L, Else L, Barber T, Mora-Peris B, Back D, Boffito M, Winston A. The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age. Hiv Clinical Trials. 16: 39-42. PMID 25777188 DOI: 10.1179/1528433614Z.0000000006 |
0.334 |
|
| 2014 |
Arenas-Pinto A, Winston A, Stöhr W, Day J, Wiggins R, Quah SP, Ainsworth J, Fleck S, Dunn D, Accoroni A, Paton NI. Neurocognitive function in HIV-infected patients: comparison of two methods to define impairment. Plos One. 9: e103498. PMID 25078406 DOI: 10.1371/journal.pone.0103498 |
0.317 |
|
| 2014 |
Williams I, Churchill D, Anderson J, Boffito M, Bower M, Cairns G, Cwynarski K, Edwards S, Fidler S, Fisher M, Freedman A, Geretti AM, Gilleece Y, Horne R, ... ... Winston A, et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight.). Hiv Medicine. 15: 1-85. PMID 24330011 DOI: 10.1111/hiv.12119 |
0.318 |
|
| 2014 |
Garvey LJ, Pavese N, Politis M, Ramlackhansingh A, Brooks DJ, Taylor-Robinson SD, Winston A. Increased microglia activation in neurologically asymptomatic HIV-infected patients receiving effective ART. Aids (London, England). 28: 67-72. PMID 23887068 DOI: 10.1097/01.Aids.0000432467.54003.F7 |
0.317 |
|
| 2013 |
Winston A, Arenas-Pinto A, Stöhr W, Fisher M, Orkin CM, Aderogba K, De Burgh-Thomas A, O'Farrell N, Lacey CJ, Leen C, Dunn D, Paton NI. Neurocognitive function in HIV infected patients on antiretroviral therapy. Plos One. 8: e61949. PMID 23646111 DOI: 10.1371/journal.pone.0061949 |
0.322 |
|
| 2013 |
Mora-Peris B, Croucher A, Else LJ, Vera JH, Khoo S, Scullard G, Back D, Winston A. Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects. The Journal of Antimicrobial Chemotherapy. 68: 1348-53. PMID 23364475 DOI: 10.1093/jac/dkt006 |
0.309 |
|
| 2013 |
Croucher A, Winston A. Neurological complications of HIV Medicine (United Kingdom). 41: 450-455. DOI: 10.1016/j.mpmed.2013.05.003 |
0.332 |
|
| 2012 |
Williams I, Churchill D, Anderson J, Boffito M, Bower M, Cairns G, Cwynarski K, Edwards S, Fidler S, Fisher M, Freedman A, Geretti AM, Gilleece Y, Horne R, Johnson M, ... ... Winston A, et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. Hiv Medicine. 13: 1-85. PMID 22830364 DOI: 10.1111/J.1468-1293.2012.01029.X |
0.314 |
|
| 2012 |
Rawson T, Muir D, Mackie NE, Garvey LJ, Everitt A, Winston A. Factors associated with cerebrospinal fluid HIV RNA in HIV infected subjects undergoing lumbar puncture examination in a clinical setting. The Journal of Infection. 65: 239-45. PMID 22522289 DOI: 10.1016/j.jinf.2012.04.007 |
0.309 |
|
| 2012 |
Winston A, Puls R, Kerr SJ, Duncombe C, Li PC, Gill JM, Taylor-Robinson SD, Emery S, Cooper DA. Dynamics of cognitive change in HIV-infected individuals commencing three different initial antiretroviral regimens: a randomized, controlled study. Hiv Medicine. 13: 245-51. PMID 22151608 DOI: 10.1111/j.1468-1293.2011.00962.x |
0.324 |
|
| 2012 |
Winston A, Garvey L. Overestimation or underestimation of neurocognitive impairment in HIV-infected cohorts? Hiv Clinical Trials. 13: 299-300. DOI: 10.1310/hct1305-299 |
0.315 |
|
| 2011 |
Garvey L, Surendrakumar V, Winston A. Low rates of neurocognitive impairment are observed in neuro-asymptomatic HIV-infected subjects on effective antiretroviral therapy. Hiv Clinical Trials. 12: 333-8. PMID 22189152 DOI: 10.1310/hct1206-333 |
0.308 |
|
| 2010 |
Garvey L, Latch N, Erlwein OW, Mackie NE, Walsh J, Scullard G, McClure MO, Dickinson L, Back D, Winston A. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients. Antiviral Therapy. 15: 213-8. PMID 20386076 DOI: 10.3851/IMP1517 |
0.336 |
|
| Show low-probability matches. |